AK127

DRUG3 trials

Sponsors

Akesobio Australia Pty Ltd, Akeso

Conditions

Advanced Solid TumorsAdvanced or Metastatic Solid TumoursHepatocellular Carcinoma

Early Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

CompletedNCT05021120

Akesobio Australia Pty LtdAdvanced or Metastatic Solid Tumours

Start: 2021-10-12End: 2025-04-01Updated: 2025-12-04

Phase 1

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

AkesoAdvanced Solid Tumors

Start: 2022-06-30End: 2024-06-30Target: 36Updated: 2022-05-26

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

RecruitingNCT06530251

AkesoHepatocellular Carcinoma

Start: 2024-09-24End: 2028-09-01Target: 280Updated: 2026-03-04